Alkeon Capital Management
STML

Alkeon Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Alkeon Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-650,500
Closed -$3.15M – 158
2020
Q1 		$3.15M Sell
650,500
-175,000
-21% -$1.13M 0.01% 126
2019
Q4 		$8.78M Hold
825,500
– – 0.03% 110
2019
Q3 		$8.59M Buy
825,500
+615,000
+292% +$8.05M 0.03% 119
2019
Q2 		$3.23M Buy
210,500
+55,500
+36% +$803K 0.01% 136
2019
Q1 		$1.99M Buy
155,000
+85,000
+121% +$961K 0.01% 122
2018
Q4 		$665K Buy
70,000
+30,000
+75% +$389K ﹤0.01% 118
2018
Q3 		$664K Buy
+40,000
New +$641K ﹤0.01% 122

Alkeon Capital Management's STML Position: Q2 2020 in Review

Alkeon Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 650,500 shares — an estimated $3.15M sold.

Alkeon Capital Management first reported a position in STML in Q3 2018 and held it in 7 quarters. The position peaked at $8.78M in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Alkeon Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Alkeon Capital Management sold 650,500 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $3.15M.
  • Alkeon Capital Management first reported a position in Stemline Therapeutics, Inc. in Q3 2018 and held it in 7 quarters.
  • Alkeon Capital Management's Stemline Therapeutics, Inc. position peaked at $8.78M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Alkeon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.